Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
The projected business potential is around US$ 1 million in the first year
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Subscribe To Our Newsletter & Stay Updated
